Clinical Trials Logo

Pancreas Cancer clinical trials

View clinical trials related to Pancreas Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT02905578 Active, not recruiting - Pancreas Cancer Clinical Trials

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Start date: November 28, 2018
Phase: Phase 2
Study type: Interventional

This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment).

NCT ID: NCT02206360 Active, not recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Early Detection Program

PCEDP
Start date: April 2014
Phase:
Study type: Observational [Patient Registry]

Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.

NCT ID: NCT02089269 Active, not recruiting - Pancreas Cancer Clinical Trials

Tumor Registry Pancreatic Cancer

AMETHYST
Start date: December 2013
Phase:
Study type: Observational [Patient Registry]

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

NCT ID: NCT02021422 Active, not recruiting - Pancreas Cancer Clinical Trials

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Start date: June 2013
Phase: Phase 1
Study type: Interventional

The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and clinical activity information, overall survival, and serious adverse events related to the study drug.

NCT ID: NCT01771146 Active, not recruiting - Pancreas Cancer Clinical Trials

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

Start date: October 2012
Phase: N/A
Study type: Interventional

A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)

NCT ID: NCT01448668 Active, not recruiting - Pancreas Cancer Clinical Trials

Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)

Start date: September 2010
Phase: N/A
Study type: Observational

Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu ("quercus", i.e. from oak tree) in patients with pancreatic cancer (Union for International Cancer Control, UICC stages II-IV), in addition to conventional oncological therapy (radio-, chemo-, targeted therapy) as compared to a parallel group with conventional therapy only. Primary Endpoints: Reduction of adverse effects of conventional therapy; reduction of therapy or disease induced symptoms (both are quality of life parameters and evaluated after 1 year); prolongation of disease free and/or overall survival (DFS, OS) after 3 years. Prospective observational confirmation study of previous retrospective cohort study. As this is a non-interventional cohort study, all therapies and measurements are performed on directive by the treating physician and/or request by the patient only.